Adverse effects of antimalarial drugs, excluding cardiac toxicity;Effets indesirables des antimalariques, cardiotoxicite exclue

Medecine et Maladies Infectieuses

Volumn 29, Issue SUPPL. 3, 1999, Pages 326-332

  Rouveix, B ^a  

^a université Paris Cité   (France)

Author keywords

Adverse effects; Antimalarial drugs

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PROGUANIL; QUININE;

ADVERSE DRUG REACTION; CONFERENCE PAPER; DRUG SAFETY; DRUG TOLERANCE; HUMAN; MALARIA; NEUROTOXICITY; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 0033398221     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Luzzi GA, Peto TEA. Adverse effects of antimalarials. An update. Drug Saf 1993 ; 8 : 295-311.
2. Drewitt PN, Butterworth KR, Springall CD, Walters DG, Raglan EM. Toxicity threshold of quinine hydrochloride following low-level repeated dosing in healthy volunteers. Food Chem Toxicol 1993 ; 31 : 235-45.
3. Pawar R, Jacobs GH, Smith MC. Quinine-associated acute interstitial nephritis. Am J Kidney Dis 1994 ; 24 : 211-4.
4. Story D, Hall A, Older P. Quinine-induced haemolytic uraemic syndrome [letter]. Anaesth Intensive Care 1994 ; 22 : 114-5.
5. Limburg PJ, Katz H, Grant CS, Service FJ. Quinine-induced hypoglycaemia. Ann Intern Med 1993 ; 119 : 218-9.
6. Phillips-Howard PA, Ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact or fiction? Drug Saf 1995 ; 12 : 370-83.
7. Ajayi AA, Oluokun A, Sofowora O, Akinleye A, Ajayi AT. Epidemiology of antimalarial-induced pruritus in Africans. Eur J Clin Pharmacol 1989 ; 37 : 539-40.
8. Mnyika KS, Kihamia CM. Chloroquine-induced pruritus: its impact on chloroquine utilization in malaria control in Dar es Salaam. J Trop Med Hyg 1991 ; 94 : 27-31.
9. Lange WR, Frankenfield DL, Moriarty-Sheehan M, Contoreggi CS, Frame JD. No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg 1994 ; 51 : 389-92.
10. Tester-Dalderup CBM. Antiprotozal drugs. In: Dukes MNG, ed. Meyler's side effects of drugs. Elsewier; 1996. p. 799-822.
11. Courtois X, Vincent F, Legoff F. Crises convulsives après phrophylaxie par chloroquine. Presse Méd 1993 ; 22 : 315.
12. Di Perri G, Olliaro P, Nardi S, Deganello R, Allegranzi B, Bonora S, et al. Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands. Acta Trop 1998 ; 70 : 25-33.
13. Peto TEA. Toxicity of antimalarial drugs. J R Soc Med 1989 ; 84 : 30-4.
14. Olliaro P, Nevill C, Le Bras J, Ringwall P, Mussano P, Garner P, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996 ; 348 : 1196-201.
15. Raccurt CP, Arouko H, Djossou F, Macaigne F, Massougbodji A, Zohoun T, et al. Sensibilité in vivo du Plasmodium falciparum à l'amodiaquine dans la ville de Cotonou et ses environs (Bénin). Méd Trop 1990 ; 50 : 21-5.
16. Nevill CG, Verhoeff FH, Murafu CG, Ten Hove WR, Van der Kaay HP, Were JB. A comparison of amodiaquine and chloroquine in the treatment therapy of falciparum malaria in Kenya. East Afr Med J 1994 ; 71 : 167-70.
17. Mc Intosh HM, Greenwood BM. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria. A systematic review. Ann Trop Med Parasitol 1998 ; 92 : 265-70.
18. World Health Organisation. Reports on individual drugs. Mefloquine: an uptade on safety issues. Who Drug Information 1996 ; 10: 58-61.
19. Cook GC. Adverse effect of chemotherapeutic agents used in tropical medicine. Drug Saf 1995 ; 13 : 31-45.
20. Stürchler D, Handschin J, Kaiser D, Kerr L, Mittelhozer ML, Reber R, et al. Neuropsychiatrie side-effects of mefloquine. N Engl J Med 1990 ; 322 : 1752-3.
21. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993 ; 44 : 257-65.
22. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. Br Med J 1996 ; 313 : 13-6.
23. Carme B, Peguet C, Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997 ; 2 : 953-6.
24. Schlagenhauf P, Steffen R, Lobel H, Johson R, Letz R, Tschopp A, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996 ; 1 : 485-94.
25. Schlagenhauf P, Lobel H, Steffen R, Johson R, Popp K, Tschopp A, et al. Tolerance of mefloquine by swissair trainee pilots. Am J Trop Med Hyg 1997 ; 56 : 235-40.
26. Winstanley P. Mefloquine: the benefits outweight the risks. Br J Clin Pharmacol 1996 ; 42 : 411-3.
27. Van Riemsdijk MM, Van der Klauw MM, Van Heest JAC, Reedeker FR, Ligthelm RJ, Herings RM, et al. Neuropsychiatrie effects of antimalarials. Eur J Clin Pharmacol 1997 ; 52 : 1-6.
28. Ronn AM, Ronne-Rasmussen J, Gotzsche PC, Bygbjerg IC. Neuropsychiatrie manifestations after mefloquine therapy for P. falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 1998 ; 3 : 83-8.
29. Croft AMJ, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997 ; 91 : 199-203.
30. ® for malaria prophylaxis in non immune volunteers. Trop Med Parasitol 1993 ; 44 : 254-6.
31. Ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3 673 patients. Bull WHO 1995 ; 73 : 631-42.
32. Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army Service-women. J Infect Dis 1997 ; 176 : 831-3.
33. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr 1996 ; 16 : 281-6.
34. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990 ; 83 : 82-4.
35. ®? Méd Afr Noire 1995 ; 42 : 350-61.
36. Laing ABG. Studies on the chemotherapy of malaria. I. The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in the Gambia. Trans R Soc Trop Med Hyg 1970 ; 64 : 562-8.
37. Bartelloni PJ, Sheehy TW, Tigertt KD. Combined therapy for chloroquine-resistant Plasmodium falciparum infection. Concurrent use of long-acting sulphormethoxine and pyrimethamine. J Am Med Assoc 1967 ; 199 : 173-7.
38. Nosten F, Priced RN. New antimalarials. A risk-benefit analysis. Drug Saf 1995 ; 12 : 264-73.
39. Kremsner PG, Wildling E, Jenne L, Graninger W, Bienzle U. Comparison of micronized halofantrine with chloroquine-antibiotic combination for treating Plasmodium falciparum malaria in adults from Gabon. Am J Trop Med Hyg 1994 ; 50 : 790-5.
40. Ezeamuzie IC, Igbigbi PS, Ambakederemo AW, Abila B, Kwaejike IN. Halofantrine-induced pruritus amongst subjects who itch to chloroquine. J Trop Med Hyg 1991 ; 94 : 184-8.
41. Ramsay AR, Msaki EP, Kennedy K, Ngowi FI, Gillespie SA. Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute, Plasmodium falciparum malaria. Ann Trop Med Parasitol 1996 ; 90 : 461-6.
42. Watt G, Loesuttiviboon L, Jongsakul K, Shanks D, Ohrt CK, Karnasuta C, et al. Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg 1994 ; 50 : 187-92.
43. Fourcade L, Gachot B, de Pina JJ, Heno P, Laurent T, Touze JE. Choc anaphylactique associé au traitement du paludisme par halofantrine. Presse Méd 1997 ; 26 : 559.
44. Orlando G, Isabella L, Atzori C, Cargnel A. Blackwater fever after halofantrine. Lancet 1996 ; 347 : 1408-9.
45. Wilding E, Jenne L, Graninger W, Bienzle U, Kremsner PG. High dose chloroquine versus micronized halofantrine in chloroquine resistant Plasmodium falciparum malaria. J Antimicrob Chemother 1994 ; 33 : 871-5.
46. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf 1996 ; 14 : 131-45.
47. Drysdale SF, Philips-Howard PA, Behrens RH. Proguanil, chloroquine and mouth ulcers. Lancet 1990 ; 335 : 164.
48. Daniels AM. Mouth ulceration associated with proguanil. Lancet 1986 ; ii : 269.
49. Touze JE, Keundjian A, Fusai T, Doury JC. Human pharmacokinetics of chloroquine and proguanil delivered in a single capsule for malaria chemoprophylaxis. Trop Med Parasitol 1995; 46: 158-60.
50. Dupuy O. Étude de tolérance de l'association chloroquine-proguanil dans la prophylaxie antipalustre de 131 militaires ayant séjourné en RCA. Med Mal Inf 1992 (Special) : 621-3.
51. Houben MH, Hoorntje SJ. Pancytopenia due to paludrine. Nephron 1995 ; 71 : 368.
52. Carme B, Péguet C, Nevez G. Chimioprophylaxie du paludisme : tolérance et observance de la méfloquine et de l'association proguanil-chloroquine chez des touristes français. Bull Soc Pathol Exot 1997 ; 90 : 273-6.
53. White NJ. The treatment of malaria. N Engl J Med 1996 ; 335 : 800-6.
54. Due DD, De Vries PJ, Nguyen XK, Le Nguyen B, Kager PA, Van Boxtel CJ. The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am J Trop Med. Hyg 1994 ; 51 : 785-90.
55. Kager PA, Schultz MJ, Zijlstra EE, Van den Berg B, Van Boxtel CJ. Arteether administration in human: preliminary studies of pharmacokinetics, safety and tolerance. Tans R Soc Trop Med Hyg 1994 ; 88 Suppl 1 : 53-4.
56. Van Hensbroeck MB, Onyiorah E, Jaffar S, Schneider G, Palmer A, Frenkel J, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996 ; 335 : 69-75.
57. Tran TH, Day NPJ, Nguyen HP, Nguyen TH, Tran TH, Pham PL, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83.
58. Miller LG, Panosian CB. Ataxia and slurred speech after artenusate treatment for falciparum malaria [letter]. N Engl J Med 1997 ; 336 : 1328.
59. Mohanty S, Mishra SK, Satpathy SKI, Dash S, Patnaik J. Alpha, beta artemether for the treatment of complicated falciparum malaria. Trans R Soc Trop Med Hyg 1997 ; 91 : 328-30.
60. White NJ. Artemisinin: current status. Trans R Soc Trop Med Hyg 1994 ; 88 Suppl 1 : 3-4.
61. Bunnag D, Kanda T, Karbwang J, Thimasarn K, Pungpak S, Harisanuta T. Artemether and artenusate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1996 : 90 : 415-7.
62. Cao XT, Bethell DB, Pham TP, Ta TT, Tran TN, Nguyen TT, et al. Comparison of artemisin suppositories, intramuscular artenusate and intravenous quinine for the treatment of severe childrood malaria. Trans R Soc Trop Med Hyg 1997 ; 91 : 335-42.
63. De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996 ; 52 : 818-36.
64. Radloff PD, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmidium falciparum malaria. Lancet 1996 ; 347 : 1511-4.
65. Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, et al. Efficacy and safety of atovaquone-proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998 ; 27 : 494-9.
66. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998 ; 351 : 709-13.